140 related articles for article (PubMed ID: 25112396)
21. Hodgkin lymphoma-associated paraneoplastic cerebellar degeneration on FDG-PET/CT.
Gheysens O; Deroose CM; Tousseyn T; Goffin K; Verhoef G; Dierickx D
Br J Haematol; 2014 Feb; 164(4):468. PubMed ID: 24460525
[No Abstract] [Full Text] [Related]
22. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
23. Optimizing positron emission tomography image acquisition protocols in integrated positron emission tomography/magnetic resonance imaging.
Hartung-Knemeyer V; Beiderwellen KJ; Buchbender C; Kuehl H; Lauenstein TC; Bockisch A; Poeppel TD
Invest Radiol; 2013 May; 48(5):290-4. PubMed ID: 23399811
[TBL] [Abstract][Full Text] [Related]
24. FDG PET/CT methodology for evaluation of treatment response in lymphoma: from "graded visual analysis" and "semiquantitative SUVmax" to global disease burden assessment.
Basu S; Zaidi H; Salavati A; Hess S; Carlsen PF; Alavi A
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2158-60. PubMed ID: 24993455
[No Abstract] [Full Text] [Related]
25. Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas.
Wong CY; Thie J; Parling-Lynch KJ; Zakalik D; Margolis JH; Gaskill M; Hill J; Qing F; Fink-Bennett D; Nagle C
J Nucl Med; 2005 Oct; 46(10):1659-63. PubMed ID: 16204716
[TBL] [Abstract][Full Text] [Related]
26. Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.
Tseng D; Rachakonda LP; Su Z; Advani R; Horning S; Hoppe RT; Quon A; Graves EE; Loo BW; Tran PT
Radiat Oncol; 2012 Jan; 7():5. PubMed ID: 22260710
[TBL] [Abstract][Full Text] [Related]
27. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
[TBL] [Abstract][Full Text] [Related]
28. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
29. Response-Adapted Treatment Strategies in Hodgkin Lymphoma Using PET Imaging.
Bair SM; Svoboda J
PET Clin; 2019 Jul; 14(3):353-368. PubMed ID: 31084775
[TBL] [Abstract][Full Text] [Related]
30. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?
Gallamini A; Kostakoglu L
Blood; 2012 Dec; 120(25):4913-20. PubMed ID: 22932799
[TBL] [Abstract][Full Text] [Related]
31. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?
Kostakoglu L; Gallamini A
J Nucl Med; 2013 Jul; 54(7):1082-93. PubMed ID: 23818548
[TBL] [Abstract][Full Text] [Related]
32. Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma.
Kobe C; Dietlein M; Fuchs M
Leuk Lymphoma; 2010 Mar; 51(3):552-3. PubMed ID: 20141443
[No Abstract] [Full Text] [Related]
33. Early interim PET scan in Hodgkin lymphoma: where do we stand?
Gallamini A; Hutchings M; Avigdor A; Polliack A
Leuk Lymphoma; 2008 Apr; 49(4):659-62. PubMed ID: 18398732
[TBL] [Abstract][Full Text] [Related]
34. Interobserver variability in interim PET assessment in Hodgkin lymphoma-reasons and solutions.
Georgi TW; Kurch L; Hasenclever D; Warbey VS; Pike L; Radford J; Sabri O; Kluge R; Barrington SF
PLoS One; 2023; 18(3):e0283694. PubMed ID: 36976821
[TBL] [Abstract][Full Text] [Related]
35. Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes.
Terasawa T; Nagai H
Leuk Lymphoma; 2009 Nov; 50(11):1750-2. PubMed ID: 19863179
[TBL] [Abstract][Full Text] [Related]
36. Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases.
Molin D; Hagberg H; Suurküla M; Aström G
Acta Oncol; 2010 May; 49(4):526-8. PubMed ID: 20397779
[No Abstract] [Full Text] [Related]
37. The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: a meta-analysis and commentary on published studies.
Ziakas PD; Poulou LS; Voulgarelis M; Thanos L
Leuk Lymphoma; 2012 Nov; 53(11):2166-74. PubMed ID: 22512238
[TBL] [Abstract][Full Text] [Related]
38. Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.
Adams HJ; Kwee TC
Eur J Haematol; 2016 Dec; 97(6):491-498. PubMed ID: 27528557
[TBL] [Abstract][Full Text] [Related]
39. Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study.
Pommier P; Dussart S; Girinsky T; Chabaud S; Lagrange JL; Nguyen TD; Beckendorff V; D'Hombres A; Artignan X; Bondiau PY; Carrie C; Giammarile F
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):823-8. PubMed ID: 20452732
[TBL] [Abstract][Full Text] [Related]
40. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
Kostakoglu L; Schöder H; Johnson JL; Hall NC; Schwartz LH; Straus DJ; LaCasce AS; Jung SH; Bartlett NL; Canellos GP; Cheson BD;
Leuk Lymphoma; 2012 Nov; 53(11):2143-50. PubMed ID: 22421007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
